Speaker Profile

M.D., Senior Vice President Clinical Translation, Fate Therapeutics

Biography
Sarah Cooley, M.D., M.S. is Senior Vice President, Clinical Translation at Fate Therapeutics and oversees translational medicine across the cell-based cancer immunotherapy programs and for early clinical development of cell product candidates. Dr. Cooley, an expert in the field of natural killer (NK) cell receptor immunogenetics and in the clinical development of NK cell cancer immunotherapies, brings to Fate Therapeutics more than 12 years of leadership in the field of NK cell clinical research and development. Prior to joining Fate, she was an Associate Professor of Medicine in the Division of Hematology, Oncology and Transplantation at the University of Minnesota where her clinical practice included adult Hematologic Malignancy and Blood and Marrow Transplant service and her research included leading 15 clinical trials of NK cell or immunotherapy-based cancer treatments. At the University of Minnesota’s Masonic Cancer Center, Dr. Cooley played a critical role in the development of translational research infrastructure, serving as the Medical Director for the Clinical Trials Office, for the Oncology Informatics Shared Resource and as Director of the Cancer Research Translational Initiative. Dr. Cooley received an undergraduate degree in Biology and Chemistry from Cornell University and graduated from the University of Minnesota Medical School. She completed a residency in Internal Medicine at the University of California, San Francisco and fellowship training in Hematology and Oncology at the University of Minnesota, where she also received her M.S. in Clinical Research from the School of Public Health.


 Session Abstract – PMWC 2022 Silicon Valley


Track Chair:
Ira Mellman, Genentech

Human cells have been successfully used as treatment for blood cancers for decades but translating the promise to cell-based treatment for solid tumors has been slow. The advent of gene-editing techniques such as CRISPR, coupled with advances in our understanding of immunology and optimization of growing, manufacturing, transporting, storing, and handling specialized biological samples and materials is transforming the cell therapy field. We will hear in this session about some of the most promising work in the field, as well as the challenges in overcoming resistance

    Sessions:
  • Recent Advances in Cell-based Therapy
    Session Chair: Ira Mellman, Genentech
    - Nicholas Haining, ArsenalBio
    - Elliot Norry, Adaptimmune
    - Sarah Cooley, Fate Therapeutics
    - Tina Alberton, Lyell
  • Patentability of Immunotherapies - Latest Developments
    - Janet Xiao, Morrison & Foerster LLP
  • Cell-based Therapy Challenges
    Session Chair: Lawrence Corey, Fred Hutchinson Cancer Research Center
    - Sharon Benzeno, Adaptive Biotechnologies
    - Arati Rao, PACT Pharma
    - Mark Kotter, bit.bio
  • Next Generation siRNA RX
    - Joe Gray, OHSU
  • Next-generation Supply Chain For Cell & Gene Therapies
    Session Chair: Sharon Benzeno, Adaptive Biotechnologies
    - Amy DuRoss, Vineti
    - Tim Moore, Pact Pharma
    - Teresa Foy, BMS
  • Biomarkers to Guide Immunotherapy
    Session Chair: Danny Wells, ImmunAI
    - Sanjeev Mariathasan, Genentech
    - Christine Spencer, PICI
    - Klaus Lindpaintner, InterVenn Bioscience
  • Advances in Multi-Omic Spatial Profiling
    Session Chair: Sarah Warren, NanoString Technologies
    - Chris Corless, OHSU
  • Engineered Therapeutics
    Session Chair: Daniel Chen, SITC
    - Kole Roybal, UCSF
    - Paul Parren, Lava Therapeutics
    - Sonja Schrepfer, UCSF